The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
May 16th 2024
These data highlight the effects of psoriasis on the mental health of adolescents in Denmark.
New Indications for Psoriasis Drug Cosentyx Receive FDA Nod
Biologic drug secukinumab (Cosentyx/Novartis), already FDA approved in January 2015 to treat chronic plaque psoriasis, has now been approved for two new indications: the treatment of active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).
Psoriasis Treatment May Trigger Significant Adverse Effects
Study results suggest that a treatment for psoriasis and multiple sclerosis may induce a dangerous adverse effect, particularly in women. The finding is potentially important, because while treatment with fumaric acid esters has been around for more than 40 years, it is now being used more widely in the United States, Germany, and other areas.
Q&A With Kevin Cooper From University Hospital: Looking at Dermatology From the Genetic Level
Calling dermatology the study of the skin only begins to scratch the surface of the field. While environmental factors have been thoroughly looked at, advancements in technology are allowing doctors and researchers to look for deeper issues affecting their patients.
10-Year Follow-up Study on Safety and Efficacy of Adalimumab
Study shows that adalimumab led to sustained clinical and functional responses in nearly one-third of treatment-refractory patients who completed 10 years of treatment. Patients with shorter disease duration achieved better outcomes, highlighting the need for early treatment.
IL-Targeted Biologics for Treatment of Psoriasis Show Promising Efficacy
A recent review looked at the immunopathogenesis of psoriasis, identified key mediators of psoriatic plaques that are being targeted by new and emerging biologic therapies, and highlighted the latest efficacy and safety data from trials of these new agents.
Guselkumab Effective for Treatment of Moderate-to-Severe Plaque Psoriasis
Researchers are learning more about the safety and efficacy of anti-interleukin-17 and anti-interleukin-23 (IL-23) therapy, although there are several agents currently under investigation. Anti-TNF agents and IL agents target psoriatic inflammation through different pathways.
Novel Anti-Interleukin-23 Therapy Outperformed Current Treatment in Patients with Plaque Psoriasis
Successful preliminary trials revealed that treatment with a novel anti–interleukin-23 monoclonal antibody, guselkumab, (CNTO 1959/Janssen) was more effective at reducing the symptoms of plaque psoriasis than adalimumab.
Retrospective Study Confirms Need for LTBI Screening Prior to Starting Biologic Therapy
Inflammatory chronic diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis bring many treatment challenges. Among them is the fact that biologic therapies for these diseases-particularly anti-TNF agents-while effective, can themselves bring reactivation of a latent tuberculosis infection.
American Medical Association Wins Concessions on ICD-10 Switch
Coming next from Medicare: the ICD-10 Obmudsman. Billing under the dreaded new International Classification of Diseases-10 (ICD-10) coding system will get a bit less onerous under a deal brokered between Medicare and the American Medical Association.
Investigational Aerosol Foam Brings Rapid Itch Relief for Patients with Plaque
Aerosol foam calcipotriol/betamethasone diproprionate (Enstilar/LEO Pharma) has been shown to successfully and rapidly relieve itchiness and improve itch-related sleep loss in patients suffering from psoriasis vulgaris (plaque psoriasis).